Irgass

Bromfenac, the active ingredient in Irgass, is a nonsteroidal anti‑inflammatory drug presented as an ophthalmic solution for ocular use. It is indicated for the treatment of post‑operative inflammation and pain following eye surgery as well as for managing general ocular inflammation. The formulation provides rapid ocular absorption, helping to reduce discomfort and swelling quickly.

GNH USA supplies Irgass as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company ensures quality assurance and regulatory compliance across all shipments.

Bromfenac is an NSAID used to manage ocular inflammation.

Post‑operative inflammation and pain after ocular surgery: reduces swelling and discomfort, facilitating faster visual recovery. Ocular inflammation: alleviates redness, edema, and pain associated with inflammatory eye conditions. Ocular pain: provides rapid relief of discomfort caused by various eye irritations.

Bromfenac ophthalmic solution may cause ocular adverse reactions, ranging from mild irritation to rare serious events.

Common Side Effects: - Eye irritation - Redness - Foreign body sensation - Tearing

Serious or Rare Side Effects: - Corneal ulceration - Increased intraocular pressure - Severe allergic reaction (e.g., angioedema) - Vision loss

When prescribing bromfenac ophthalmic solution, several precautions should be observed to ensure patient safety. - Pregnancy: safety not established; use only if potential benefit justifies the risk. - Breastfeeding: unknown excretion; consider discontinuation or monitor infant. - Concomitant ocular infection: assess risk of worsening infection before use. - Known hypersensitivity to bromfenac or other NSAIDs: contraindicated due to risk of allergic reactions. - Contact lens wearers: may experience increased irritation; advise removal during treatment. - Store at room temperature: keep in original container, protect from light and moisture.

Bromfenac may interact with other medications, affecting ocular or systemic safety.

Major Interactions (Avoid): - Systemic NSAIDs: additive risk of systemic adverse effects such as bleeding. - Anticoagulants (e.g., warfarin): potential for increased ocular bleeding. - Corticosteroid eye drops: may delay wound healing when used together.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: possible alteration of intraocular pressure control. - Other ophthalmic agents (e.g., mydriatics): monitor for additive irritation.